Cracking Cancer’s Code: How AI and RWE are Driving Trials Forward 

October 9th, 2025
11 a.m. EDT

Oncology drug development is often at the forefront of innovation, answering the call to accelerate timelines, personalize treatments, and improve patient access. The same is true when it comes to advanced technologies and strategies like Artificial Intelligence (AI) and Real-World Evidence (RWE). Together with evolving regulatory requirements, AI and RWE are reshaping oncology trials.

Dive into the details with our expert speakers as they discuss the current regulatory landscape, including the FDA’s AI initiatives, guidance on RWE, and how global agencies are approaching AI in drug development. They’ll explore practical applications of AI and RWE across the clinical lifecycle of an oncology program, from enhancing diagnostic accuracy and optimizing patient recruitment to enabling personalized medicine and post-marketing surveillance.

Register for the webinar to better understand how AI and RWE can drive smarter, faster oncology development while staying aligned with regulatory expectations.

Attendees will gain insights into:

• The global regulatory landscape and appetite for RWE and AI in drug development
• The role of RWE and AI in oncology clinical trials
• Forward-looking trends and ways to adapt to a future with more AI-enabled trials

Speakers:

Meera Belur – Executive Director, Oncology Program Strategy

Cathy Gatza, PhD – Vice President, Regulatory Strategy